2.08
+0.005(+0.24%)
Currency In USD
| Previous Close | 2.07 |
| Open | 2.08 |
| Day High | 2.13 |
| Day Low | 2.06 |
| 52-Week High | 4.55 |
| 52-Week Low | 1.31 |
| Volume | 411,477 |
| Average Volume | 682,027.3 |
| Market Cap | 147.38M |
| PE | -1.42 |
| EPS | -1.46 |
| Moving Average 50 Days | 2.12 |
| Moving Average 200 Days | 2.01 |
| Change | 0.01 |
If you invested $1000 in Nkarta, Inc. (NKTX) since IPO date, it would be worth $43.32 as of September 30, 2025 at a share price of $2.075. Whereas If you bought $1000 worth of Nkarta, Inc. (NKTX) shares 3 years ago, it would be worth $157.67 as of September 30, 2025 at a share price of $2.075.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nkarta to Participate in a September Investor Conference
GlobeNewswire Inc.
Sep 02, 2025 12:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following inv
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.
Jul 23, 2025 12:01 PM GMT
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwrigh
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
GlobeNewswire Inc.
Jun 06, 2025 12:52 PM GMT
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appoint